MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-16-2023
Athersys Net Income 2011-2026 | ATHX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Athersys
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -87 M | -78.8 M | -44.6 M | -24.3 M | -32.2 M | -15.3 M | -16.4 M | -22.1 M | -30.7 M | -14.7 M | -13.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.7 M | -87 M | -34.5 M |
Quarterly Net Income Athersys
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.77 M | -12.9 M | -7.81 M | - | -13.7 M | -23.6 M | -22.2 M | -21.7 M | -16.2 M | -49.1 M | -26.5 M | -22.2 M | -22.5 M | -18.4 M | -15.6 M | -9.92 M | -12 M | -9.69 M | -13 M | -11.3 M | -9.74 M | 6.93 M | -10.2 M | -13.1 M | -7.24 M | -6.27 M | -5.63 M | -7.13 M | -6 M | -6.96 M | 4.75 M | 3.59 M | -6.5 M | -1.04 M | -12.5 M | -6.55 M | -4.72 M | 675 K | -11.5 M | -9.8 M | -5.61 M | -5.95 M | -9.39 M | -3.24 M | -3.45 M | -3.71 M | -4.34 M | -4.25 M | -2.34 M | -3.22 M | -3.93 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.93 M | -49.1 M | -9.81 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amgen
AMGN
|
7.71 B | $ 350.54 | 0.79 % | $ 189 B |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 19.39 | -0.56 % | $ 906 M | USA |
 |
Altimmune
ALT
|
-88.1 M | $ 3.45 | 3.14 % | $ 304 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-221 M | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.62 | 0.21 % | $ 16.5 M | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 219.22 | -1.2 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Benitec Biopharma
BNTC
|
-8.8 M | $ 11.01 | 0.27 % | $ 453 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-62.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Compugen Ltd.
CGEN
|
35.3 M | $ 2.12 | 1.44 % | $ 198 M |  Israel |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
168 M | $ 1.58 | 3.95 % | $ 185 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Cellectis S.A.
CLLS
|
-125 M | $ 3.39 | 1.5 % | $ 116 M | France |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-16.6 M | $ 0.6 | -1.79 % | $ 6.87 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
-220 M | $ 12.85 | 0.86 % | $ 774 M | USA |
 |
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
CorMedix
CRMD
|
163 M | $ 6.43 | 2.88 % | $ 463 K | USA |
 |
Cara Therapeutics
CARA
|
-119 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-132 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-19.8 M | - | -74.18 % | $ 955 K | USA |
 |
CytomX Therapeutics
CTMX
|
-17.4 M | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-265 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
-423 M | $ 21.1 | 4.59 % | $ 3.47 B | USA |
 |
Dyadic International
DYAI
|
-6.8 M | $ 0.9 | -4.79 % | $ 25.9 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-72.8 M | $ 4.29 | 1.06 % | $ 712 M | Canada |